Temsirolimus in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome Clinical Trial

— TEMDS  

Official title:

Treatment of MDS Patients With Single Agent Temsirolimus - a Pilot Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01111448
• Other study ID #: TUD-TEMDS1-042
• Status: Terminated
• Phase: Phase 2
• First received: April 23, 2010
• Last updated: February 12, 2015
• Start date: April 2010
• Est. completion date: June 2014

Study information

• Verified date: February 2015
• Source: Technische Universität Dresden
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The goal of this Pilot-study is to evaluate the response of unselected MDS patients to temsirolimus a drug approved for the treatment of renal cell cancer. It is planned to give temsirolimus at a weekly dose of 25 mg as intravenous infusion for a maximum duration of 12 months. Regular bone marrow biopsies are planned for controlling MDS response.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: June 2014
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >18 years at the time of signing the informed consent form;

• Patients able to understand the consequences of participating in this trial and not having any disorders or other circumstances (i.e. being in ward or imprisoned) which keeps them from giving written informed consent;

• cytologically or histologically established diagnosis of de novo or therapy-related MDS according to the FAB-classification, either previously treated or untreated, presenting with:

• Group I (low-risk): Low- or INT-1 risk features according to IPSS and requiring at least 4 units of red blood cells within the last 8 weeks prior to screening visit or presenting with neutropenia (<1 Gpt/l neutrophils) or

• Group II (high-risk): INT-2 or HIGH-risk IPSS refractory or intolerant to 5-Azacytidine.

CMML patients of dysplastic phenotype (WBC < 13 Gpt/l) may be included in both arms according to IPSS. CMML patients showing proliferative phenotype (WBC >=13 Gpt/l) will be included in the high risk arm;

• not eligible for an immediate allogeneic HSCT or conventional chemotherapy;

• all previous MDS specific therapies (except supportive approaches like transfusions or antibiotics) must have been discontinued at least 4 weeks prior to study enrollment;

• ECOG performance status of <= 3 at study entry;

• laboratory test results within these ranges:

• Serum creatinine <= 177 µmo/l (<= 2.0 mg/dL);

• total bilirubin <= 3 x ULN;

• AST (SGOT) and ALT (SGPT) <= 3 x ULN;

• total fasting cholesterol <= 9.1 mmol/l (350 mg/dl);

• fasting triglyceride level <= 4.5 mmol/l (400 mg/dl);

• platelets > 25 Gpt/l without transfusion support in patients with LOW- and INT-1 Risk according to IPSS;

• signed informed consent.

Exclusion Criteria:

• For Patients with LOW- or INT1-Risk according to IPSS: Thrombocytopenia below 25 Gpt/l (INT2- and HIGH-IPSS patients may be included irrespective of platelet count);

• known hypersensitivity to temsirolimus, sirolimus or any components of the infusion solution (dl-alpha-tocopherol, propylene glycol, anhydrous citric acid, polysorbate 80, polyethylene glycol 400, dehydrated alcohol);

• known hypersensitivity to macrolid antibiotics (because of structural similarities between this class of antibiotics and study medication);

• any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study;

• known positive for HIV or any other uncontrolled infection;

• presence of any other malignancy being not in complete remission for at least 3 years (previous chemotherapy for other malignancies is not an exclusion criteria);

• necessity of therapeutic anticoagulation (excluding low dose ASS);

• participation in an other clinical trial within the last 4 weeks;

• pregnant or breast feeding females (lactating females must agree not to breast feed while on study);

• females of childbearing potential (FCBP) except those fulfilling at least one of the following criteria:

• post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with serum FSH > 40 U/ml);

• post-surgery (6 weeks after bilateral ovarectomy with or without hysterectomy);regular and correct use of contraceptives with a PEARL Index of < 1% (e.g. implants, depot formulations of hormones, oral contraceptives, intra uterine device - IUD);

• sexual abstinence;

• partner, who had vasectomy (confirmed by two negative analyses of semen);

• male patients, who do not agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 3 months following discontinuation from the study even if he has undergone a successful vasectomy;

• patients with a history of chronic drug abuse or another illness which does not allow the patient to assess the nature and/or possible consequences of the study;

• patients who are not likely to follow the trial protocol (lack of willingness to cooperate).

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Preleukemia

Intervention

Drug:
• Temsirolimus
25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min

Locations

Country	Name	City	State
Germany	Klinikum Chemnitz Klinik für Innere Medizin III	Chemnitz
Germany	Universitätsklinikum C. G. Carus der TU Dresden	Dresden
Germany	Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klin. Immunologie	Düsseldorf
Germany	Universitätsmedizin Göttingen Georg-August-Universität Abteilung Hämatologie und Onkologie	Goettingen
Germany	Forschungsgesellschaft mbH	Leipzig
Germany	Universitätsklinikum Leipzig AöR	Leipzig
Germany	Klinikum Mannheim GmbH III. Medizinische Universitätsklinik -SP Hämatologie/Onkologie	Mannheim

Sponsors (2)

Lead Sponsor	Collaborator
Technische Universität Dresden	Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall hematological response rate using modified IWG criteria (combination of CR, PR, marrow-CR and SD with HI).		at 4 months	No
Secondary	Toxicity as measured by NCI CTCAE v3.0		4 and 12 months	Yes
Secondary	Overall survival		1 year	No
Secondary	Progression-free-survival		1 year	No
Secondary	Rate of leukemic progression		1 year	No
Secondary	Overall hematological response rate using modified IWG-criteria		1 year	No
Secondary	Quality of life as measured by EORTC-QLQ30		4 months, 12 months	No